Sphene CapitalDespite the recent stock market rally and declining volatility, IPOs are rather rare in many industrialised countries –not least for seasonal reasons. The main reason for this, however, is the aggressive monetary policy of the central banks, with more than ten interest rate hikes in both Europe and the US.
Tag Archive for: obesity
Following in the footsteps of the European Medicines Agency (EMA), the US FDA is now also investigating the side effects of obesity blockbusters.
In the race for global market share of its obesity and diabetes blockbuster semaglutide, Novo Nordisk is expanding production in Europe.
Stock markets love investment concepts, calling the robust ones ‘megatrends’. Golden ageing is one such megatrend banking on the fact that business can extract more from people living longer. Such megatrend investments help – up to the moment when rising interest rates crash the party.
With a US$1bn acquisition of Canadian Inversago Pharma, Novo Nordisk A/S fiights to maintain its dominant position in the booming weight loss drug market.
Novo Nordisk A/S invests €726m to expand facilities and to produce APIs to supply the company’s global clinical trials.